AMIX

Autonomix Medical, Inc. (AMIX) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2025. Autonomix Medical, Inc. is a pre-revenue, clinical-stage medical device company developing a catheter-based platform for sensing and treating disorders of the peripheral nervous system. The company's lead system targets intractable pain associated with pancreatic cancer. The filing reflects a 1-for-20 reverse stock split effective October 24, 2024, with all share and per-share data retroactively adjusted.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by 24% to $3.421 million from $2.753 million.
  • Research and Development (R&D): Increased 67% to $1.593 million, driven by clinical trial and product development costs.
  • General and Administrative (G&A): Increased 2% to $1.828 million, primarily due to higher legal and professional fees.
• Capital Structure: The company completed an At-Market (ATM) issuance in the quarter, selling 1,304,260 shares for net proceeds of approximately $2.1 million. Additionally, remaining convertible notes from a 2023 bridge offering were fully converted into common stock in March 2025.
• Stock-Based Compensation: Increased slightly to $388,000 from $360,000 in the prior year period.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management estimates current cash resources ($8.6 million) are sufficient to fund operations only into the second calendar quarter of 2026. The filing explicitly states that these factors raise "substantial doubt" about the company's ability to continue as a going concern within one year. Additional financing of approximately $32 million to $40 million is estimated to be required to reach commercialization.
• Clinical Progress: The company completed enrollment in its first-in-human proof-of-concept study (PoC 1) for pancreatic cancer pain, reporting statistically significant pain reduction. In June 2025, the company initiated PoC 2, expanding the study to include other visceral cancers (gallbladder, liver, bile duct).
• Regulatory Path: Following a pre-submission meeting with the FDA, the company targets submitting 90-day GLP data by the end of 2025 and initiating an Early Feasibility Study (EFS) in the first half of 2026, with a potential De Novo approval targeted for 2028.
• Subsequent Events (Post-June 30, 2025):
  • Warrant Inducement: In July 2025, the company entered an agreement to reduce the exercise price of existing warrants, raising approximately $2.6 million in gross proceeds.
  • Cost Reduction: In July and August 2025, the company entered into stock option cancellation agreements with employees, officers, and board members in exchange for severance packages to reduce future cash burn.
• Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting due to a lack of segregation of duties and limited staffing, concluding that disclosure controls were not effective as of June 30, 2025.

Investor Verification Checklist

• Verify the timeline and terms of the July 2025 warrant inducement and the resulting dilution impact on existing shareholders.
• Confirm the specific cash runway given the "substantial doubt" going concern warning and the estimated $32M-$40M funding gap.
• Review the details of the stock option cancellations with executives and board members to assess the impact on future compensation expenses and retention risks.
• Monitor the status of the fractional share inquiry regarding the 2024 reverse stock split, as the company is currently disputing a request to issue ~271,846 shares.
• Assess the progress of the PoC 2 clinical trial and the timeline for the FDA Early Feasibility Study (EFS) submission.